Chironian Fall/Winter 2009 by New York Medical College
Touro Scholar 
The Chironian NYMC Archives Publications 
Fall 2009 
Chironian Fall/Winter 2009 
New York Medical College 
Follow this and additional works at: https://touroscholar.touro.edu/nymc_arch_journals 
 Part of the Higher Education Commons, and the Medicine and Health Sciences Commons 
Recommended Citation 
New York Medical College. (2009). Chironian Fall/Winter 2009. Retrieved from 
https://touroscholar.touro.edu/nymc_arch_journals/52 
This Book is brought to you for free and open access by the NYMC Archives Publications at Touro Scholar. It has 
been accepted for inclusion in The Chironian by an authorized administrator of Touro Scholar. For more 




TB: Still a Fearsome Foe
Fostering an Abiding 
Respect for Humanity 
Affordable Healthcare: 
Power to the People
Fall/Winter 2009
chironian
New York Medical College
The findings suggest that further investigation is  
needed to evaluate the potential impact of medical 
liability concerns on the medical care system, and hint 
toward the importance of medical tort reform as one 
way to reduce healthcare costs and improve quality. 
One way might be to foster more judicious  
prescription of antibiotics based on science and  
evidence rather than on risk aversion.
“Relationship Between Population Density  
of Attorneys and Prevalence of Methicillin- 
Resistant Staphylococcus aureus: Is Medical-
Legal Pressure on Physicians a Driving Force 
Behind the Development of Antibiotic  
Resistance?” American Journal of Therapeutics, 
September-October 2009.  
Online at http://www.americantherapeutics.com.
Targeting the best delivery point for a 
new spinal cord injury treatment 
Due to the hazardous nature of combat, war veterans 
represent about 22 percent of spinal cord injury 
(SCI) cases. While the steroid methylprednisolone is 
considered the standard treatment to restore function, 
improvement is modest and the treatment is associ-
ated with muscle weakness and immunosuppression. 
Researchers are seeking new treatments for this 
debilitating injury that affects predominantly younger 
soldiers with irreversible paralysis.
Before potential new treatments can be studied  
with human patients, they must show efficacy in an  
appropriate animal model of SCI. Preliminary data 
from research led by Richard J. Zeman, Ph.D., 
associate professor of cell biology and anatomy, shows 
that targeted stereotactic X-irradiation (SXI) of the 
injury site increased locomotor function following SCI.
Fear of lawsuits may prompt some 
doctors to overprescribe antibiotics
Methicillin resistance in Staphylococcus aureus, or 
MRSA, is one of the most feared resistant organisms 
that clinicians treat given its virulence and ability 
to cause infections in a variety of clinical settings. 
Its prevalence in hospitals in the United States and 
around the world is increasing, conferring severe 
consequences on patient morbidity, mortality, utiliza-
tion of health care resources, and medical care costs.
In a new study led by George Sakoulas, M.D., 
assistant professor of medicine, and four other 
NYMC faculty, the authors hypothesized that 
medical liability concerns may be playing a role 
in the increase of MRSA in healthcare settings by 
encouraging clinicians to prescribe antibiotics more 
often and more broadly than clinical circumstances 
and evidence-based guidelines warrant.
The researchers analyzed census figures, statistics on 
attorney and physician densities, and data on antibi-
otic utilization for the United States, Canada and 15 
European countries, to determine the percentage 
of methicillin resistance among clinical isolates of S. 
aureus. They found a strong correlation between the 
prevalence of methicillin resistance and density of 
attorneys in countries in Europe and North Amer-
ica. They found no correlation between prevalence 
of methicillin resistance and physician density. 
Investigators surveyed 162 healthcare providers  
to identify that medical liability concerns were as  
important as antibiotic cost and formulary  
restrictions in selecting treatment regimens. The 
surveys also confirmed that physicians were more 
concerned about medical liability in cases of  
underprescribing antibiotics rather than by  
overprescribing them.
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Doris Bucher, Ph.D., associate professor of microbiology and immunology, illustrates how to make a new vaccine to deal 
with an old/new influenza virus that’s come to call some 30 years after its last appearance. The orange and blue balls she 
holds represent two different flu viruses. To prepare the 2009 H1N1 vaccine seed virus, special eggs were infected with 
the old high growing strain, A/PR/8/34 (orange) and the new 2009 H1N1 virus isolate (blue). The genes from the two 
viruses reassorted to produce high growing seed viruses for the 2009 H1N1 vaccine. Dr. Bucher named the new seed 
viruses NYMC X-179A and NYMC X-181, in honor of New York Medical College.
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(By)passing the Salt
It’s not just stress and diet that can cause  
hypertension.  Ashok Kumar, Ph.D., and his team  
pursue genetic clues in transgenic mice that could  
account for almost half the risk. 
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Think you know the causes of hypertension—obesity, too much dietary salt, psychological stress, obesity and  testosterone? You’re only partly right. Ashok Kumar, 
Ph.D., professor of pathology, is quick to point out that lifestyle  
factors typically fingered as culprits account for only about half of 
the risk related to the disease, which is known to affect some 50 
million Americans. 
What accounts for the remaining 45 percent of the inter-individual 
differences in blood pressure? The answer lies in genetics, a field 
in which Dr. Kumar conducts sophisticated research that has lately 
garnered him a five-year NIH grant for almost $2 million. Together 
with another $2 million grant he received from the NIH three years 
ago, the funds assure that Dr. Kumar will continue his exploration 
into hypertension’s genetic and molecular basis. 
“It has been known for a long time that genetics plays an important 
role in hypertension,” Dr. Kumar says. “If parents have increased 
blood pressure, there is an increased chance their children will have 
it too.” But there is more to it than that, and his two grants focus 
on the transcriptional regulation of genes affecting available levels 
of angiotensin-II, the molecule that plays a critical role in tightening 
blood vessels and thereby raising blood pressure. 
Even though two classes of blood-pressure drugs—angiotensin- 
converting enzyme (ACE) inhibitors and angiotensin-receptor  
blockers (ARBs)—targeting the system that Dr. Kumar studies are 
already on the market, his research goes deeper, into their genetic 
and molecular underpinnings. 
After first identifying naturally occurring variants in the genes that 
code for angiotensinogen, the molecular precursor to angiotensin, 
Dr. Kumar’s team has showed that these single-nucleotide  
polymorphisms, as they are called, form distinct haplotypes 
—genetic variations that are usually inherited as a group. He  
identified two commonly occurring haplotypes, AA or AG, in a 
region that promotes how many copies of the angiotensinogen gene 
are transcribed by RNA. The genetic variants have been found to 
play an active role in both men and women, as well as in Caucasians,  
Japanese and African-Americans. 
“Dr. Kumar has been among the first to look at the genetic  
regulation of the angiotensinogen gene,” said Alberto Nasjletti, M.D., 
professor of pharmacology and a past president of the Inter-Ameri-
can Society of Hypertension. “We have a number of drugs that can 
treat hypertension, but they basically treat the symptoms. Dr. Kumar 
has shown that variations in the angiotensinogen gene may be  
playing an important role. It’s an active area of investigation, and  
his lab is well recognized in the area.”
By Dan Hurley
CHIRONIAN • New York Medical College    3
From cell culture to in vivo 
To understand the role of the AA or AG haplotypes in living organ-
isms, Dr. Kumar’s laboratory generated transgenic mice containing one 
or the other. In doing so, his became the first and, still to this day, the 
only laboratory in the world to develop such mice. The animals were 
also given the human version of the gene for renin, which is necessary 
for cleaving human angiotensinogen. 
In a study published in the December 2008 American Journal of 
Physiology—Regulatory, Integrative and Comparative Physiology, Dr. Kumar 
and colleagues showed that male mice with the AA haplotype had 
human angiotensinogen levels that were 60 percent higher in their 
livers and 40 percent higher in their kidneys than those with the AG 
haplotype. What’s more, levels of angiotensin II circulating in the blood-
stream of male AA mice were about 50 percent higher than the levels 
in male AG mice, and the first group’s blood pressure averaged 8 mm/
Hg higher. The study was the first to demonstrate in vivo that a genetic 
polymorphism in the promoter of a human gene ultimately leads to an 
increase in blood pressure.
“Now that we have transgenic mice with human genes in them, these 
can be used as a model system.” Dr. Kumar says. “Right now we’re 
working with the transgenic animals to try to understand how the 
genes are regulated in vivo. Once we know the basic mechanisms, it 
will be easier to develop new drugs. Then the mice could be used to 
see if a candidate drug is lowering blood pressure or not.”
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It’s not just stress and diet that can cause  
hypertension.  Ashok Kumar, Ph.D., and his team  
pursue genetic clues in transgenic mice that could  
account for almost half the risk. 
The laboratory team of Ashok Kumar, Ph.D. (seated right), is the world’s 
first to develop transgenic mice containing human genes that enable the 
study of angiotensinogen. Seated to his left is Sudhir Jain, Ph.D., research 
assistant professor of pathology. Standing are Varunkumar Pandey, Ph.D. 
candidate, and postdoctoral fellows Shreekrishna Maharjan, Ph.D., Andrej 
Tillinger, Ph.D., and Brahmaraju Mopidevi, Ph.D.
“It has been known for a long time 
that genetics plays an important 
role in hypertension. If parents 
have increased blood pressure, 
there is an increased chance their 
children will have it too.”
– Ashok Kumar, Ph. D. 
Dr. Kumar’s group began their study of the angiotensinogen gene  
and angiotensin receptor gene by conducting association studies 
comparing hundreds of people with hypertension to an equal number 
of subjects without the disorder. They found strong statistical evidence 
that the AA haplotype of the angiotensinogen gene was associated with 
higher blood pressure, and that the AG version was associated with 
normal blood pressure.
Their next task was to identify the complex molecular steps by which 
the two haplotypes orchestrate how much angiotensin II will end up 
being produced. 
“That part we did in cell culture,” Dr. Kumar says. “And cell culture is fine, 
but then we wanted to do it in vivo, in the living organism.”
Now that his pioneering work elucidating the mechanisms behind the 
different haplotypes is nearly completed, he says, “We’re mainly  
working with the transgenic animals to try to understand how the genes 
are regulated in vivo. We measure their blood pressure all day and night. 
We take plasma to measure angiotensin levels. We also take different 
organs—the liver, kidney and heart—to examine how the genes are 
expressed in these tissues.”
Of course, the particular genes he’s been focused on are not the only 
ones affecting blood pressure. “When it comes to real life,” he says, 
“there are always multiple genes regulating a complex disease like  
hypertension. We are looking at these other genes now.” 
Stress, obesity and inflammation
Moreover, he’s looking at the genetic underpinnings of how stress,  
obesity and inflammation each play a role in blood pressure. “They may 
have completely different genes involved than the ones regulating  
angiotensinogen,” he says.
Recent studies have shown, for instance, that interleukin-6 (IL-G), an 
immune-system cytokine that plays an important role in mediating 
inflammation, increases the expression of the human angiotensinogen 
gene in liver cells. In a paper published in the May 2007 American Journal 
of Physiology—Cell Physiology, Dr. Kumar and colleagues concluded that 
three transcription factors that bind to the human angiotensinogen gene 
are responsible for the IL-6 induced promoter activity. 
For all the uncertainties that remain, the understanding of essential hy-
pertension has made dramatic advances in recent decades, says John A. 
McClung, M.D., associate professor of clinical medicine, in the cardiology 
division of the Department of Medicine.
“It was initially called ‘essential hypertension’ because it was necessary for 
functioning as people age. If you tried to lower it, you’d kill them,” says Dr. 
McClung, who has provided blood samples of hypertensive patients used 
in Dr. Kumar’s research. “That’s why guys like Franklin Roosevelt and  
Winston Churchill could walk around with blood pressures that would 
knock your socks off. It was really only in the 1950s and ’60s that  
antihypertensives started to be used with any frequency. Even now,  
etiology remains a substantial mystery. That’s why Dr. Kumar’s work is  
so interesting—and it’s just beginning.” 
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Sitting behind a desk piled with copies of recent studies—“These are 
our lifeline. We have to stay up to date,” he says—Dr. Kumar views with 
equanimity a field whose complexity seems to grow more byzantine 
with each passing day. 
“It’s a very complicated system,” he says with a smile. “It begins with  
angiotensinogen, a protein that is 450 amino acids long and is  
synthesized in the liver. Then it’s cleaved by renin, which is synthesized 
in the kidney, into a peptide 10 amino acids long. Then a third enzyme, 
angiotensin converting enzyme, converts this into a peptide 8 amino 
acids long. This is the biologically active molecule, angiotensin II.”
Nature, he says, has evolved “a very complicated way to control the 
renin-angiotensin system. And the system has evolved differently  
between species. Mouse renin will not cleave human angiotensin.”
Medical Sciences in New Delhi, he returned to the United States in 
1979. He continued his research at universities in Texas, Massachusetts 
and Brooklyn,  N.Y., before joining the College as a professor in the  
department of pathology in 1994, where he has been working ever 
since on genes related to hypertension. 
His research into the genetics of hypertension has even struck home.
“My wife Sashi is hypertensive. I am not,” he says. “Six or seven years 
ago, I took samples of my blood and her blood, and we analyzed this 
particular genetic variant. We found yes, she has the variant linked to 
hypertension and I do not. I thought that was interesting.” It sure seems 
to support his hypotheses. p
“We have a number of drugs that can treat hypertension, but they basically 
treat the symptoms. Dr. Kumar has shown that variations in the  
angiotensinogen gene may be playing an important role. It’s an active  
area of investigation, and his lab is well recognized in the area.”
– Alberto Nasjletti, M.D.
The graph at left shows blood 
pressure readings over a 24-hour 
period for transgenic mice. The 
blue line displays BP readings 
from mice with a gene associated 
with hypertension, while the red 
line shows BP readings from mice 
representing “normal” subjects—
those without hypertension.
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Dr. Kumar is a Fellow of the American Heart Association’s Council for High 
Blood Pressure Research, and has served as a member of the Vascular Biology 
and Hypertension and Microcirculation study sections of the NIH. He has 
also been a reviewer for many prominent journals, including Hypertension, the 
American Journal of Hypertension, Human Heredity and others. 
Born in the northern Indian city of Rampur, Dr. Kumar conducted his post-
doctoral research at the University of Wisconsin in the laboratory of H.G. 
Khorana, Ph.D. , winner of the Nobel prize in physiology or medicine in 1968. 
Dr. Kumar remained there from 1966 to 1970, working on creating the first 
biologically active synthetic DNA molecule. After serving as assistant  
professor in the department of biochemistry at the All India Institute of  
Tracking Hypertension Using Genetic Clues
Blood Pressure Increases in  
Transgenic Mice containing  
Human Angiotensinogen Gene 
Associated with Hypertensive  
Subjects
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On the trail of a new 
drug to combat deadly  
drug-resistant TB
A novel weapon against a global killer may come from  
interfering with the ability of the bacteria’s DNA to replicate.
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Yuk-Ching Tse-Dinh, Ph.D., professor of biochemistry and molecular biology, 
is investigating the role of an enzyme, topoisomerase I, as a weapon against 
Mycobacterium tuberculosis, which has been mounting a distressingly  
powerful resistance to the current arsenal of drugs being deployed against it.
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Tuberculosis kills someone every 20 seconds. That’s almost 1,800,000 people a year worldwide, according to the World Health Organization’s estimate. If you were to invent a 
frightening conundrum of a disease, you couldn’t do better than TB. 
It is highly contagious and often fatal if untreated, and 98 percent 
of the deaths occur among the poorest of the poor in developing 
countries. TB does have a cure, but the treatment is a complicated 
six-to-nine month, multi-drug regimen developed more than 40 
years ago. It is difficult, if not impossible, for many of the sickest 
patients to complete.
Combine improper or incomplete treatment, the slow-growing 
TB bacteria (Mycobacterium tuberculosis, or M.tb.), and antibiotics in 
use since the 1960s, and the upshot is that any TB bacilli that have 
developed resistance to a drug multiply easily, until the majority in 
the body are resistant. That leads to multidrug-resistant (MDR-) 
or extensively drug-resistant (XDR-) TB, which are exponentially 
more difficult, time-consuming, and costly to treat—and are more 
frequently fatal. 
There can be another complication. An estimated one-third of the 
40 million people living with HIV/AIDS are also infected with TB, 
but the current drug treatment for TB is not compatible with many 
antiretroviral therapies for HIV.
A faster, more effective cure for TB would ultimately save millions of 
lives, especially if a drug could be developed that killed TB bacteria 
in a new way so that people with strains of TB that had developed 
resistance to existing drugs could also be treated. This is the goal of 
Yuk-Ching Tse-Dinh, Ph.D., professor of biochemistry and  
molecular biology.  With support from the Global Alliance for TB 
Drug Development (TB Alliance) since May 2009, she is studying 
whether inhibiting an M.tb. enzyme, topoisomerase I (Topo I), would 
kill the bacteria. The researcher is developing methods to identify 
Topo I inhibitors, which could then become the basis for new drugs 
that could be used against both drug-sensitive and drug-resistant TB.
“One of our goals at the TB Alliance is to stock the TB drug pipeline 
with promising and innovative research projects, such as the work 
with topoisomerase I inhibitors being conducted in partnership with 
Dr. Tse-Dinh’s team,” said Zhenkun Ma, Ph. D., TB Alliance’s chief 
scientific officer.
College experts concur. “One-third of the world’s population is 
infected with M.tb.,” observes Gary P. Wormser, M.D., director of the 
Division of Infectious Diseases and vice chairman for research in the 
Department of Medicine. “Drug discovery for TB has been far too 
slow and unproductive, and a novel drug to treat TB that is both safe 
and effective would be most welcome.”
By Cynthia A. Read
antibiotics such as Cipro® disrupt the 
function of bacterial type II topoisomerases, 
killing the bacteria. 
Dr. Tse-Dinh, who is considered the leading 
world expert on bacterial Topo I, first  
became interested in the enzymes that con-
trol the function of DNA while an under-
graduate at Hollins University in Roanoke, Va. 
She pursued her Ph.D. in biological chemistry 
at Harvard University with James C. Wang, 
Ph.D., who discovered the first DNA topo-
somerase, E. coli Topo I. Since that time she 
has focused her research on the structure, 
function and regulation of Topo I. In 1988, 
she was recruited by Dr. Isidore Danishefsky, 
chair of Department of Biochemistry and  
Molecular Biology, which was aiming to 
establish a research laboratory in her field.
“A major research goal of my group,” says 
Dr. Tse-Dinh, “is discovering antibacterial 
compounds that work against bacterial Topo 
I.” This would be a first, she claims—no such 
compounds have been identified by any 
other researcher. In 2005, Dr. Tse-Dinh and 
her team demonstrated that bacteria are 
rapidly killed when they produce mutant 
varieties of Topo I that mimic the effects of 
inhibiting the enzyme’s ability to rejoin DNA. 
They began using M.tb. Topo I as a model 
for studying how the enzyme functions, and 
she was struck by its therapeutic potential 
against TB. 
“I presented my research results and ideas 
to the TB Alliance, and they agreed to work 
with us to pursue M.tb. Topo I as a therapeutic 
target,” says Dr. Tse Dinh. The need for new 
drugs was never more clear to her than when 
she heard presentations on the global impact 
of TB at a scientific conference at Oxford 
University last summer. In countries such as 
India and South Africa, where the disease is 
rampant, many people with TB cannot afford 
the time or money to travel to a distant 
hospital, relying at best on local clinics. The 
consequences of faulty treatment and quickly 
spreading disease are human and economic 
devastation. 
Toward a faster, more effective drug
Dr. Tse-Dinh and her team are currently 
working to develop an automated screening 
method that can rapidly sort through tens of 
thousands of compounds to detect potential 
Topo I inhibitors. These inhibitors will be 
evaluated for their effectiveness against the 
purified M.tb. Topo I enzyme, using additional 
biochemical assays. The research is going 
well, and early next year Dr. Tse-Dinh will be 
discussing renewal of the partnership with the 
TB Alliance, as well as possibly seeking support 
from the NIH. 
“Drug discovery for TB has been far too 
slow and unproductive, and a novel drug 
to treat TB that is both safe and effective 
would be most welcome.” 
      – Gary P.  Wormser, M.D.– 
The plates at left and below show type I and type 
II topoisomerases, enzymes that assist the  
unwinding and rewinding of the DNA spiral. At 
left, diagram shows the type I topoisomerase 
making a break on one strand of DNA and 
passing another single strand through the 
break. Below, type II topoisomerases can pass 
a double strand of DNA through with breaks in 
both strands. Jocelyn E. Krebs, Elliott S. Goldstein, 
Stephen T. Kilpatrick, Lewin’s Essential Genes, 2010: 
Jones and Bartlett Publishers, Sudbury, Mass. www.
kbpub.com. Reprinted with permission.
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Controlling DNA
For any living cell to divide and multiply, the 
tightly coiled double helix spiral of DNA must 
unwind, separate, reproduce, and then rewind. 
The strands of DNA must also separate to 
allow the synthesis of RNA. Topoisomerases 
are enzymes that facilitate this unwinding and 
rewinding by cutting the strand of DNA and 
then, at the end of the process, connecting it 
again. Type I topoisomerases, including Topo I, 
cut one strand of the helix, while type II cuts 
both strands. Some well-known antibiotics 
and cancer drugs operate by interfering with 
the activities of topoisomerases. For example, 
the broad-spectrum fluoroquinolone  
“We have data that indicate treatment with Topo I and Topo II  
inhibitors in combination therapy may be synergistic, possibly  
speeding up treatment.”         
– Yuk-Ching Tse-Dinh, Ph. D. 
One major benefit of a TB drug based on  
inhibiting Topo I would be that the mode of action 
is new, so TB bacteria would not have developed 
resistance to it. But Dr. Tse-Dinh also believes that 
such a drug could be faster and more effective 
than current drugs. She has shown that when E. 
coli bacteria face high temperatures or oxidative 
stress, Topo I is involved in turning on the genes 
that respond to this stress. If the same holds true 
for M.tb., then a Topo I inhibitor would have an 
additional method of attacking the deadly bacteria 
during the body’s response to infection. Moreover, 
some quinolone antibiotics, which target Type II 
topoisomerase, are already being used as second-
line drugs for MDR-TB. Says Dr. Tse-Dinh, “We 
have data that indicate treatment with Topo I and 
Topo II inhibitors in combination therapy may be 
synergistic, possibly speeding up treatment.”
Dr. Tse-Dinh had been working closely on this 
project with the TB Alliance, which has the largest 
TB drug pipeline in the world. Its network 
of research partners allows for a smooth 
flow throughout the drug discovery process, 
something much appreciated by scientists 
who do not have to assume the burden of 
finding the appropriate laboratory or  
institution to take their research to the next 
step. In this case, after the Topo I inhibitors 
are identified and validated against the  
purified enzyme in Dr. Tse-Dinh’s laboratory, 
the TB Alliance could arrange for studying 
the action of the successful inhibitors on the 
entire M.tb. organism and in animal models 
of TB.
TB and beyond
The journey from molecular and biochemi-
cal research to a proven drug takes many 
years and billions of dollars, all the more so 
with a disease like TB, with its torpid bacterial 
growth rate and lengthy treatment protocol. 
But with the possibility of a Topo I inhibitor drug 
showing promise, Dr. Tse-Dinh takes the long 
view. Without her years of basic research and 
studies on the biochemistry of topoisomerase, 
she emphasizes, she would not now be in a  
position to pursue drug discovery. And with 
drug-resistant bacteria a growing problem in 
many infectious diseases—think of methicillin-
resistant Staphylococcus aureus (MRSA) 
—she hopes her work will inspire researchers 
to explore the potential of bacterial Topo I as a 
model target for other diseases. p
It takes a tough researcher to do battle with drug 
resistant TB, and Dr. Tse-Dinh (front and center) 
relies on her hardworking team of associates to keep 
up the fight. From left are Ph.D. candidates I-Fen 
Liu, Gagandeep Narula, Sandra Aedo and Jeanette 
Sutherland. To the right of Dr. Tse-Dinh are Jennifer 
Becker, research technician,  Arasu Annamalai, Ph.D., 
postdoctoral fellow, and Bokun Cheng, M.S.,  
research associate.
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Influenza pandemics are the earthquakes of human health. No matter how closely they are studied, there is no accurate way to predict when they will recur. And there is no way to prevent the death and destruction that ensue when the Richter scale 
trips past five, although proper construction, like vaccination, could mitigate disaster in 
both instances. 
Each year, the CDC selects strains of seasonal influenza virus for development of vaccine 
“seed” strains by a microbiology laboratory at New York Medical College, where the 
viruses are reassorted, cloned, amplified and eventually shipped to manufacturers that 
supply the entire world population. This seasonal vaccine must be remade each year 
because the influenza virus, which annually kills 36,000 in the U.S. alone, has one of the 
highest mutation rates of any pathogen. But without warning, 
the genome may change, resulting in a virus capable of 
producing infection that reaches every population 
on earth. Doris Bucher, Ph.D., the  
associate professor of microbiology and  
immunology who directs the College  
laboratory, has spent her 40-year career 
studying influenza, preparing for a  
pandemic she knew would come. Now 
that it has, she fully expects the influenza 
vaccine her laboratory has developed—
Novel A(H1N1), still occasionally 
referred to as the swine flu—to save 
many lives.
Naysayers don’t agree
If only it were that easy. Initial surveys 
in the fall indicated that only 50 
percent of adults said they 
would get the swine flu 
vaccine, although 75 
percent reported 
they intend to take 
their children for 
the injections 
or nasal spray 
vaccine.
The CDC sent Doris Bucher, Ph.D., traces 
of a novel influenza virus. In 23 days she 
had turned it around for production, 
and now the NYMC vaccine is on the 
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In recent years, the seasonal flu shot has  
become a high public health priority for 
healthcare workers, children, pregnant 
women and those over 50. These  
recommendations go beyond the original  
target populations of the elderly and those 
with chronic or life threatening diseases.  But 
those in targeted groups that have been 
expanded through new regulations and 
precautionary requirements don’t seem to 
be rushing out to be immunized, and the 
parameters keep changing for priority in the 
swine flu vaccination. 
It was 1976 the last time a pandemic was 
predicted, and that time it didn’t happen. But 
don’t push your luck,  Dr. Bucher say. She ticks 
off what everyone needs to know about this 
year’s swine flu model:
n  The seasonal flu shot that has been  
available since September is 60 to 80 
percent effective in reducing your chance 
of getting the flu.  
n  You cannot get the flu from the injected 
vaccine, which is made with a killed virus, 
not a live one. The nasal spray relies on a 
live virus, and therefore is not recommend-
ed for use by pregnant women or children 
less than 2 years old. The 1976 swine flu 
“epidemic” that never was did result in a 
small number of cases with complications 
from Guillain Barre syndrome after vac-
cination, but to this day scientists do not 
know why the nervous system disorder 
occurred.
n  In 2009 one of the greatest risks of com-
plications is for pregnant women, who start 
out healthy and then develop pneumonia.  
A French research team has recently re-
vealed that in France by October 2009, half 
the women who died from complications 
were pregnant. Yet there is a reluctance 
among pregnant women to get vaccinated 
despite the protection it also gives to the 
unborn baby. Since the thalidomide disaster 
of 1958-61, after which pregnant women 
were counseled to avoid pharmaceutical 
drugs of any kind, there appears to be some 
ambivalence to getting vaccinated, which is 
controversial in itself.
How it began
It was a routine workday in April of last year 
when Dr. Bucher began reading the ProMED 
bulletin she gets every day. The global 
electronic reporting system for outbreaks of 
emerging infectious diseases and toxins  
mentioned the finding of two unique flu 
strains around the Texas/California border, 
which the CDC was analyzing. The Mexican 
epidemic was well underway. Dr. Bucher 
immediately emailed several colleagues in 
the Influenza Division at the CDC including 
Nancy Cox, Ph.D., director, and Alexander 
Klimov, Ph.D., chief, and Xiyan Xu, M.D., 
team leader, Virus Surveillance and Diagnosis 
Branch, to offer “some really good reagents 
for making high yield reassortants. The CDC 
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“It took 23 days to grow the virus and we were the first to do it. The swine flu 
seed virus that we made also grew better than seed viruses prepared  
by other labs around the world.”             – Doris Bucher, Ph. D.
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The cheerful team of scientists who populate Doris Bucher’s laboratory appear none the worse for wear after developing the 2009 H1N1 vaccine seed virus to control 
the swine flu pandemic in little more than three stressful weeks. But it’s old hat to Dr. Bucher, seated front center, and Barbara Pokorny, lab supervisor, seated left, who 
have been working on influenza vaccines their entire careers. Surrounding them are Jianhua Le, Ph.D., research assistant professor; Alex Fulvini, Ph.D. candidate; Shiroh 
Onodera, Ph.D., research associate; Yu (Arthur) He, Ph.D. candidate; Jean Marie Silverman, M.S., research technician; Manoj Kumar, Ph.D., D.V.M., research associate, and 
Rene Devis, Ph.D., research assistant. Not pictured is Ph.D. candidate Jennifer Arroyo.
called me and said, ‘Why don’t we send  
the virus to you?’” And so Dr. Bucher and  
her team were on the job, turning a flu virus 
into seed stock—a form of the virus that  
will grow rapidly in eggs so that drug  
manufacturers can use it to make hundreds 
of millions of doses of the vaccine. 
She has classified all her seed strains made 
on her watch to begin with NYMC “in  
honor of the institution,” she says. “It took 
23 days to grow the virus and we were the 
first to do it. The swine flu seed virus that 
we made also grew better than seed viruses 
prepared by other labs around the world.  
The seasonal flu vaccine we made for 2009-
2010 is called NYMC X-175C. The swine flu 
seed is NYMC X179A (a second generation 
seed is NYMC X-181). We are definitely 
making what’s out there.” 
 The 2009 swine flu virus has a complicated 
genetic history. Influenza viruses have eight 
segments, or genetic pieces of the virus. The 
2009 swine flu has three segments originating 
from American swine flu, two from Eurasian 
swine flu, two from avian influenza and one 
from human flu. The NYMC swine flu vaccine 
seed viruses prepared by reassortment are 
Pandemics” that Dr. Bucher organized in 
New York City.
Anyone glancing through the door window 
into Dr. Kilbourne’s lab during his tenure may 
remember seeing a woman swathed in white, 
seated at the bench with an egg in one hand 
and a syringe in the other. She is Barbara 
Pokorny, who had been Dr. Kilbourne’s  
assistant since he was at Mount Sinai. 
Decades later in her current position as lab 
supervisor, she is still developing flu  
reassortants in those special eggs. “The virus 
grows in the cells of the allantoic cavity of 
these specific pathogen-free eggs,” Dr. Bucher 
advises. “They cost $4.25 an egg and we go 
through 30 to 90 eggs a week.” 
Others in the Bucher lab include Jianhua Le, 
Ph.D., research assistant professor ; Jean Marie 
Silverman, M.S., research technician; Manoj 
Kumar, Ph.D., D.V.M., who performs gene 
analysis on reassortants, and Rene Devis, 
who assists in gene analysis. The laboratory  
is underwritten by IFPMA, a consortium  
of influenza vaccine manufacturers with  
headquarters in Geneva.
Model of responsibility
Dr. Bucher and her team were slightly  
shell-shocked from the crisis and were  
extremely tense for months. “We didn’t 
know how bad it would be and we wanted 
to get this vaccine out to protect the  
population. Everyone in the lab was feeling 
intense pressure,” she says. Having been the 
department course director of medical  
microbiology for 14 years, she perhaps 
handled the stress better than the others.  
“The virus is always changing and always a 
challenge. There is no other vaccine that is 
changed every year,” she states. “Once we 
were successful in developing the virus  
reassortant seed, we continued to improve 
the virus, resulting in a second generation 
seed that grew twice as well as the original.”
With her time of crisis passed, Dr. Bucher 
can only hope that the vaccine manufac-
turers will be able to increase the H1N1 
supply to match the demand, whatever that 
ultimately turns out to be.  Not that she can 
ever stop worrying about the flu altogether. 
Her lab has already started the process that 
will produce the seed for the 2010 seasonal 
influenza vaccine.p
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Lab supervisor Barbara Pokorny has been injecting 
eggs with flu viruses since the 1970s, working first 
with Dr. Edwin Kilbourne and continuing with Dr. 
Doris Bucher. The entire team felt the pressure last 
summer while pandemic fears mounted and the 
world awaited a viable vaccine.
attenuated (tamed) viruses with three  
segments from the original 2009 swine 
flu isolate, and five segments from a virus 
isolated in 1934, one that allows the virus to 
grow well in eggs, an old fashioned but  
reliable medium that Dr. Bucher still prefers. 
The master mentor
She learned much of what she knows from 
the so-called “father of the flu,” Edwin D. 
Kilbourne, M.D., emeritus professor of  
microbiology and immunology, who  
developed the first genetically engineered 
vaccine. Dr. Bucher went to work for Dr. 
Kilbourne to develop influenza vaccines at 
the department of microbiology he founded 
at the Mount Sinai School of Medicine in 
New York City. “At the time I had three other 
offers,” she recalls, “but Kilbourne’s work 
seemed to be the most important—especially 
since I had just recovered from an awful case 
of the flu! He was interested in my expertise 
in developing a vaccine consisting of purified 
proteins.” In 1987 she was recruited by the 
College’s Department of Microbiology and 
Immunology. Five years later she persuaded 
Dr. Kilbourne, already elected to the National 
Academy of Sciences, to join up, too.
“The flu vaccine manufacturers asked me 
if I would keep things going,” 
she says, “if and when Dr. 
Kilbourne decided to 
retire.” That he did in 
2002, but he still keeps 
a hand in by advising 
on all matters of the flu. 
In May he was keynote 
speaker at the New York 






Albert B.  
Lowenfels, M.D., 
IS GOING STRONG at 82
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Surgeon, teacher and researcher, he 
is currently P.I. for two epidemiology 
studies. Ready to retire? “Maybe”
By Marjorie Roberts
To all appearances, Al Lowenfels is a soft spoken gentleman of few words and cares. That may be true, but in the 82nd year of his life, when most his age have long been retired to indulge in 
pleasant pastimes and playing with their grandchildren, Albert B.  
Lowenfels, M.D., is still doing what he’s always done. One of the first 
things he does at least one day a week is to walk seven miles roundtrip 
to the New York Medical College campus from his home in Thornwood. 
He prefers to make the return trip while it is still light outside because  
“I have to pass through two graveyards,” he says with a twinkle in  
his eye.
Once he is settled in the fifth-floor cubicle in Munger Pavilion that he 
built himself over one weekend, he methodically turns to the issues that 
induced him to stop practicing general surgery 19 years ago. Teaching 
and research had captured his fancy, while the liver and pancreas, and 
the disease of alcoholism, became the objects of his most devoted 
intentions. Indeed, in his built-in office, which is as tight and efficient as  
a ship’s stateroom, Dr. Lowenfels is the proverbial happy clam. The  
cabinets, pullouts and drawers, holding the repository of his life, are  
all he needs to work and continue to thrive. 
No loss for words
When he speaks there is no searching for a word, no lapse of memory,  
no matter how long ago the incident took place. So it goes for a major 
medical conference he conceived a decade ago to celebrate the turn  
of the century—an event that turned out to be a smash hit and  
positioned the College as the region’s biomedical academic  
powerhouse. It was his idea to have eight illustrious scientists come  
and lecture to New York Medical College students, who were excused 
from classes for the day. 
“I wrote a note to everyone [I invited] and said, ‘Would you like to 
come to our millennium conference?’ It didn’t say anything about  
compensation, yet everyone said yes. I was surprised,” he admits.  
“Medicine at the Millennium” was held at a large performance hall  
at a neighboring undergraduate university to accommodate all  
Success turns his head
“Westchester was a rough and ready place when I first came here,” he 
says with a grin.
 The College made him a full professor of surgery in 1979, and two 
years later tapped him as professor of community and preventive  
medicine. Dr. Lowenfels taught medical students in every year of  
undergraduate and graduate studies, plus master of public health  
candidates in the Graduate School of Health Sciences, now the School 
of Health Sciences and Practice. The stunning range of topics he has 
taught includes biostatistics and epidemiology, surgical diagnosis and the 
history of medicine.
Through the years Dr. Lowenfels took on other assignments, such as 
director of surgery at Westchester Community Health Plan, an HMO, 
the students, faculty and guests who came to hear the likes  
of Luc Montagnier, M.D., co-discoverer of the virus that causes  
AIDS, and David A. Kessler, M.D., J.D., dean of the Yale University 
School of Medicine and former commissioner of the Food and  
Drug Administration. 
Need an idea?
Reinhard E. Zachrau, M.D., is professor of pathology at the College 
and the course director of pathology/pathophysiology, which runs 
the entire second year. He can attest to the original ideas that Dr. 
Lowenfels emits with ease, citing the Historical Clinical-Pathological 
Conference that is part of his course. A third-year student discusses 
the clinical aspects of a case concerning a person famous in a 
previous century, presenting the findings to the entire second-year 
class. James Joyce was dissected last year in the day-long event that 
evinces the progress made in treatment between the subject’s 
century and this one.
“It was Lowenfels’ idea and I jumped on it,” says Dr. Zachrau. “He  
has a researcher’s mind. He’s known internationally. And he is very  
interested in education.” Perhaps his grammar school experience 
primed him to make education an important part of his life. With  
a brief shake of his head, Dr. Lowenfels reveals that from  
kindergarten to fourth grade he attended a one-room schoolhouse 
in the Rosedale section of White Plains, N.Y. “I had 12 in my first 
grade class and only one in the fourth grade. We were lucky to  
have a blackboard!”
Interests change
A native of New Rochelle, N.Y., Dr. Lowenfels received a B.S. in 
chemistry from the University of Vermont, and his M.D. from the 
New York University School of Medicine. He interned and did his 
surgical residency at Bellevue Hospital, opening a private surgical 
practice in 1959 that “was mostly abdominal,” he says. “I always had 
a lot of patients with ruptured spleens. We had to make a diagnosis 
without the benefit of a CT-scan. A few of us put together a report 
on what we had learned—to put a patient flat on the back, with the 
knees pulled up. After tilting the table, any blood there would cause 
pain to be referred to the left shoulder.
“This turned into a study of five or six patients, which I wrote up 
and sent to the New England Journal of Medicine. This was my first 
paper in the NEJM. I was still in private practice, but the experience 
made me decide it was much more exciting to be teaching and 
doing research…It was too bad I had majored in chemistry before 
there was DNA. I might have stayed with chemistry but there were 
no role models.” What he did do was join Westchester County 
Medical Center, where he became associate director of surgery in 
1966, and director of surgical research in the Department of  
Surgery at the College one year later.
“He has a researcher’s mind. He’s 
known internationally. And he is 
very interested in education.”         
       – Reinhard E. Zachrau, M.D.
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and a stint at the International Agency for Research on Cancer.  
He found himself gravitating more to research, having decided “there is 
not much difference between research and teaching. Research is  
discovering things and teaching is helping others learn through  
discovery.” He proceeded to reinvent himself into a scientist who 
succeeded in having 18 articles printed in the New England Journal of 
Medicine alone.
Since 1966, the Christopher D. Smithers Foundation, Inc. has given Dr. 
Lowenfels and the College nearly $1 million in grants. Many of the 
studies were centered on the pancreas as he investigated the  
epidemiology of alcohol-induced acute and chronic pancreatitis and 
cancer. In 1985 Solvay Pharmaceuticals, which recently became part of 
Abbott Laboratories, began funding his unrestricted research on  
pancreatic disorders and his reputation grew as an expert on one of 
“I’m not worried  
about death.  
I just don’t want  
to be there when  
it happens.”
 –  Albert B. Lowenfels, M.D., 
quoting Woody Allen
the deadliest of all cancers. Still, he investigated whatever interested him, 
such as the large study he led on the risk of cancer among patients with 
cystic fibrosis. He presently has two active projects—the relation of the 
ABO blood groups to pancreatic cancer, and the link between the growth 
rate of polyps to colorectal cancer. He projects another year to finish 
these studies, and then, who knows?
With a “young wife” of 81, four children and a grandson who is in his 
second year of medical school, Al Lowenfels is living every day his way; 
last August he went on a walking tour of Ireland. When he is pressed to 
say something salient about life, death or the future, he prefers to quote 
Woody Allen: “I’m not worried about death. I just don’t want to be there 
when it happens.” p
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Leading Edge
(continued from inside front cover)
(continued on page 32)
The team conducted a trial on SCI-
induced rats to determine the proper 
location and optimal target volume of SXI 
to improve functional recovery. Because 
of the precision of SXI, researchers also 
wanted to determine the optimal region 
of administration to produce the most  
effective response in the rats’ rehabilitation. 
SXI was administered 20 minutes  
following the injury with a radiation beam 
centered on or close to the injury site. 
The team evaluated SXI efficacy on  
motion recovery, using a locomotor scale, 
by examining spinal cord function six 
weeks following treatment of the injury. 
The greatest increase in locomotor  
recovery was observed with SXI 
centered at 4-mm rostral to (above) 
the point of the injury. This location also 
resulted in the greatest level of tissue 
sparing following the procedure. 
The authors concluded that their results 
indicate that SXI in a region several 
millimeters rostral to the injury is most 
critical for locomotor recovery, and that 
optimizing this treatment may lead to 
a therapeutic modality for spinal cord 
injuries suitable for use in battlefield 
conditions.
“Optimal Therapeutic Target 
for Stereotactic X-irradiation in 
Experimental Spinal Cord Injury.” 
Paper presented at the Military Health 
Research Forum, a scientific meeting 
hosted by the Department of Defense 
Congressionally Directed Medical  
Research Programs, on Sept. 1, 2009.
Midlife weight gain in some 
women may be caused by  
insulin resistance
Progressive weight gain that starts in the 
fourth and fifth decades is commonly 
reported by women from all ethnic and 
socio-economic groups. Current data  
suggest that, in large and diverse sub-
populations of healthy-appearing women, 
this midlife weight gain may represent the 
earliest clinical manifestation of insulin 
resistance, evidenced by increased insulin 
response curves in the presence of  
normal glucose tolerance tests.  
Harriette R. Mogul, M.D., M.P.H., 
associate professor of clinical medicine 
and Director of Research in the Division 
of Endocrinology, coined the term  
Syndrome W to highlight its defining triad 
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In our last issue of Chironian, we ran the following survey of habits, tastes and preferences of you, our readers.  
Your responses were very enlightening, and will be used to improve the magazine and give you more of what you  
like to see in the magazine. We are extending our response deadline for the Chironian Reader Survey, and adding an  
online option so we can incorporate even more of your responses into our editorial planning. If you’d like to  
complete your survey online, go to http://www.surveymonkey.com/s/TJFGFDL
SUPPORT NEW YORK MEDICAL COLLEGE
Expand Educational Opportunities 
Each year, our students assume an increasingly heavy financial burden as the cost of a first-rate health sciences education skyrockets.  
Your gift will strengthen our tradition of reducing financial barriers for many talented and deserving students.
Enhance Academic Leadership 
New York Medical College boasts some of the brightest minds working in health sciences education and research today.   
Your gift will provide the resources needed to continue to develop this stellar academic team.
Transform Medical Education 
Having access to the latest tools and technologies is essential for training top-flight professionals.  
Your gift will prepare tomorrow’s healthcare professionals for the challenges and opportunities of 21st century medicine. 
Invest in Campus Infrastructure 
The resounding success of the Medical Education Center and recently renovated Basic Sciences Building lobby demonstrates the  
key role that beautiful and innovative facilities play in creating a desirable academic environment. Your gift will help to improve and 
maintain campus facilities at a competitive level. 
Please make a gift today. Your support could have an extraordinary impact on the College’s future.
This year, as we begin celebrating the College’s 150th anniversary, we invite you to join the many benefactors who 
are working to maintain the College’s tradition of excellence in the 21st century by investing in the Annual Fund. 
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1.  Why do you read Chironian? (Rank in order of importance)
______ News about alumni
______ News about the College, its activities and progress
______ News about students, faculty, leadership
______ Trends in research and medical education
______ The “State of the University”
______ Other ____________________________
2. How much of each issue do you read?
______Read it cover to cover
______Read or skim about half the articles
______Read only what interests me 
______Read only about people I know
______Don’t read it
3.  Please rate how much you agree or disagree with the  
following statements:
Strongly             Neutral           Strongly
Disagree              Agree
   1         2      3           4   5
The articles are interesting and informative ___________
The layout and design make it easy to read  __________
The magazine keeps me up to date on alumni  ________
The magazine keeps me informed about College  
current events and the state of the University _________
The magazine is one way to learn about trends in  
research and medical education  ___________________
The articles provide a good balance of the technical  
and the personal  _______________________________





SURVEY (continued from other side)
4.  Please rank from 1 to 5 which sections of Chironian  
interest you the most (1= most interest, 5= least interest)
______Research articles  ______University news
______Personality profiles ______Student features 
______Alumni news  ______Milestones
5.  On a scale of 1 to 5 (1= very well, 5= not well at all) rank 
each of the following for how well Chironian keeps you 
informed about:
______News about alumni
______ News about the College, its activities and  
accomplishments
______News about students, faculty, or leadership
______Trends in research and medical education
______The “State of the University”
______Other _____________________________________




7.  Which best describes your relationship to New York  
Medical College?
__Alumni (Circle: Medicine, Basic Sciences, Public Health)
__Faculty (Circle: Full-time, Part-Time, Voluntary)
__Student (Circle: Medicine, Basic Sciences, Public Health)
__Staff
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What defines us, making us uniquely human and distinct from one another? For some, it is the intangible: our ability to reason, our capacity for empathy, our soul. 
For second-year medical students Bridget Oliveri and James Naples, 
it is also the physical: hands, feet and faces.
It has been a year since Oliveri and Naples first entered  
the Alumni Gross Anatomy Laboratory and met their 
“first patients”—human cadavers whose dissection 
provided their introduction to the human body. It 
is a hallmark event in the life of a medical student, 
one that conjures a little nervousness and fear, as 
well as fascination. Oliveri and Naples anticipated 
those emotions. What they did not foresee in the 
end was a personal connection to the cadavers 
and, ultimately, a sense of their humanity. 
In the beginning there was some anxiety or, as 
Oliveri describes it, “a weird mix of excitement 
and trepidation.” She recalls “the rush” leading 
up to orientation, when students—who work 
together in groups of four—meet each other 
and observe as assisting upperclassmen remove 
the shrouds that cover the cadavers. “They pull 
back the cloth and we meet the body for the  
first time,” Oliveri says. She recalls thinking, ‘I’m  
really excited, but am I going to be the one  
who faints?’”
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Students learn much more than the  
physical structure of the human body in 
their first-year gross anatomy course.  
They also learn about respect, dignity  
and the gift of being human.
By Andrea Kott, M.P.H.
✁
Students 
Respond to the Chironian Reader Survey today and let your voice be heard!
Neither she nor Naples fainted. In fact, Matthew A. Pravetz, O.F.M., Ph.D. ’88, associate professor of cell biology 
and anatomy who, as director of the anatomy course, has taught the class—each comprising approximately 
195 incoming medical students—since 1989, paces the reveal gradually and sensitively so students have time 
to adjust. 
“We spend time getting acclimated to the whole idea that this is what we’re going to be doing for the next 
few months,” Oliveri says.
After orientation, however, things pick up and by day 7 students are removing 
and holding cadavers’ organs. “It didn’t feel like we were doing it for that long 
and we were already holding the person’s heart in our hands,” Oliveri recalls, 
sounding amazed, still.
Learning landmarks
Dr. Pravetz calls certain milestones, like holding a heart, “epiphany events.” It 
is especially telling, he says, that students recall them so vividly, a year or more 
later. “There are certain key times during the course that are so revealing to 
students,” he says. “When they see the heart in the chest where it should be 
and then when they actually take it out and hold it in their hands, everything 
gets kind of hushed in the room.”
Another epiphany experience is removing the brain, such an essential part of 
a person’s personality, life and memories, and making their first incision is yet 
another moment never to be treated lightly. Dr. Pravetz explains, “As you can 
imagine, there is a lot of anxiety and tension.” There is also a tremendous 
sense of awe.
“We treat it very reverently,” he says. “We don’t just say cavalierly, ‘Pick up 
the scalpel and give it a cut.’  We look at the whole person. We examine 
the area. We take the knife and gently and reverently make the first 
cut.” It is a vertical incision in the chest, and although the blade cuts 
through less than one-quarter inch of skin, it typically takes students 
10 minutes to complete. He says. “They do it with great respect.”
The 14-week course is divided according to the parts of the body 
to be dissected—first the chest, then the abdomen/pelvis, then the 
extremities: arms, legs, head and neck. “By the end of the second 
week we have lungs in our hands,” Dr. Pravetz says. By the end of 
the fourth week, the students are holding kidneys. In the seventh 
week they uncover the cadavers’ hands and in the ninth week, 
the feet. Not until week 10 do they see the face.
There is a reason for this timing. The hands, feet and face 
are a person’s ultimate signature. Their exposure puts an 
end to any dispassion or emotional distance the students 
may have managed to maintain and reminds them, often 
unexpectedly, of their own humanity. 
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“People assume that to train medical students  
you have to teach them to distance and separate 
themselves, that the patient is just an entity. But  
[students] readily recognize the fact that this person 
still has dignity that must be respected.
-Matthew A. Pravetz, O.F.M., Ph.D. ’88
(continued from previous page)
“You see rough hands, smooth hands, bruised hands, calloused hands, 
manicured hands. One hand might have a little bit of nail polish on 
it,” Dr. Pravetz says. “All of a sudden it brings back the person.”
The face makes us human
Once the face is exposed, the entire feeling in the room changes. 
“All of a sudden things come to a stop,” Dr. Pravetz says. “Now it’s 
not just students looking at a cadaver’s hands. Now they have a face-
to-face encounter with that individual they’ve had the privilege of 
studying up to that point. All of this packs an emotional wallop.” 
Indeed, seeing the face of his cadaver changed what had been a 
purely academic exercise into a personally spiritual experience for 
Naples. “Before you see the face you’re dealing with the body and it’s 
easy to distance yourself,” he says. “But when you see the face, that’s 
when it becomes real.” 
This empathy and concern for their first patient’s well-being is 
precisely what Dr. Pravetz is after. It is, after all, what sets the stage 
for the rest of the students’ medical training. “There seems to be an 
assumption that to train medical students you have to teach them to 
distance and separate themselves, that the patient is just an entity,” 
he says. “But students readily recognize the fact that this person still 
has dignity that must be respected.”
That respect becomes evident in the caring, almost protective way in 
which the students relate to the bodies, Dr. Pravetz says. “I see out of 
the corner of my eye how they carefully wrap the person up or how 
gently they turn the body over,” he says. It does not surprise him that 
students bond with their cadavers. 
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“You get pretty attached to your own person,” says Oliveri, who named her 
cadaver Bernie. “Throughout the lab, I kept realizing that I was holding his 
hand, almost subconsciously. I think it was a little comforting for me—and 
somehow for him.”
When Naples looks back on the year he spent in gross anatomy, he  
marvels over the generosity of the individuals who donated their bodies: 
“It is so amazing that people get to the point where they’re willing to do 
that. It makes me realize how fortunate I am as a student.”
Giving thanks
The students’ gratitude to the donors and the donors’ families is profound, 
and each spring they have the opportunity to express their feelings in a 
ceremony called the Convocation of Thanks. The ceremony, a memorial 
service of sorts, is student-created, comprising the recitation of original 
poems, reflections, and musical compositions that students perform in an 
attempt to convey their heartfelt appreciation. After the performances, 
which are held in the Nevins Auditorium before a capacity audience 
each year, the convocation moves outside for the ceremonial planting of 
a young tree in honor of the individuals whose donations of their bodies 
make the program possible. 
The Convocation of Thanks does more than give students the chance to 
articulate their gratitude. It encourages them to reflect on what they have 
learned as budding physicians and, more important, to connect the  
educational with the emotional.
“It is difficult to take at face value Gross Anatomy as an educational tool 
without being in touch with the emotional and spiritual side of it,” Naples 
says. “Both are important in helping us develop as future doctors.” p
For a doctor who is also an ordained minister, practicing  
medicine means healing body, soul and society.
A s a physician, Lucille Norville Perez, M.D. ’79, labors to  heal broken bodies. As a minister, she tends to broken spirits with the same compassion and skill she brings   to doctoring. And in trying to close the gap in access to 
affordable health care that persists between whites and minorities, 
she invokes herself as an example, a casualty of an unjust medical 
hierarchy.
“Both my parents died at 61,” recalls Dr. Perez, a resident of 
Bethesda, Md., who has kept her Brooklyn accent. “My mother was 
a diabetic with chronic renal failure, blind and an amputee when 
she died—and she was a registered nurse!” 
For Dr. Perez, who once served as national health director of the 
NAACP, mending healthcare disparities begins with instilling a sense 
of empowerment to vulnerable patients, whether they’re battling 
chronic illness or entrenched poverty. Her passion for the task goes 
back many years to when she was a pediatric resident at Long Island 
Jewish Medical Center, where she treated children with leukemia 
and cystic fibrosis. “When a child looked up at me and asked, ‘Am I 
going to die today?’ it tore my heart out, and reminded me that I had 
to keep fighting for these patients,” she says. 
A fellowship at Mount Sinai Medical Center after her residency 
placed Dr. Perez in the vanguard of adolescent medicine, then a 
fledgling specialty. “This new idea that children could see their 
health provider alone, no parents in the room, was super spooky,” 
she says. “Doctors were just arriving at the concept of teenagers  
as individuals.”  
In the early 1980s, Dr. Perez served as attending physician at 
Gouverneur Hospital in Manhattan, where she treated adolescents 
from a range of backgrounds: Asian, Latino, African-American. 
“I realized that to become a better doctor, I had to get rid of my 
personal biases,” she says. “Underneath their different skin tones 
and modes of dress, all my patients struggled with the same 
emotions: stress, anxiety and the temptation to rebel.” 
As a consultant for New York City’s Department of Health, Dr. 
Perez developed several programs for teenagers to address 
substance abuse, HIV/AIDS and pregnancy, including a “Teens and 
Tots” group for adolescent parents. She also helped start the city’s 
first school-based clinics, noting firsthand the violence that plagued 
the public education system in poor neighborhoods. 
In the minority
A growing awareness of the cards stacked against minorities 
inspired Dr. Perez to found the Cave Institute, a venture committed 
to eliminating health care disparities through research, ethics and 
advocacy. Cave was her mother’s maiden name, and that of her 
medical family of three doctors, a registered nurse and a medical 
librarian. The family tradition and values are carried on by her 
daughter Nikki, 25, now a third-year medical student at Howard 
University who aspires to a career in orthopedic surgery.
Through Cave, Dr. Perez conducted surveys of faculty at historically 
black colleges and universities, highlighting pay and funding 
disparities in comparison with similar white institutions. She also 
brought clergy into discussions, noting that “faith leaders exert 
a significant influence on beliefs and attitudes in communities 
of color.” Above all, she has tried to instill awareness among 
minorities of the obstacles that hamstring their lives. 
When her older son Juan Carlos, now 30, was growing up, Dr. 
Perez showed him the neighborhoods of Park Slope, an affluent 
white enclave of Brooklyn, and Flatbush, a poorer minority section. 
















Dr. Lucy Perez has the youthful vigor—and appearance—of a woman many 
years younger. Her passion for doing right by people impels her to take on  
challenges that ordinary folks might find daunting. Her six-year-old son JayCee 
came into her life on the wings of such a challenge.
The contrast between the manicured gardens of the 
former and trash-ridden streets of the latter prompted 
him to ask his mother why blacks “don’t get rid of 
their garbage.” She asked him to count the garbage 
cans they saw in each district. “In Park Slope, there 
was one next to every bench. In Flatbush, we went 
blocks before we saw one,” Dr. Perez says. “We must 
make clear to our children: ‘This is not my culture, this 
is not my fault. This is political oppression, unfair and 
unjust. And I don’t have to accept it.’ This way, they’re 
not paralyzed, but empowered.”
After Hurricane Katrina left poor Gulf residents 
strapped for basic health services, Dr. Perez formed 
a coalition to provide emergency health care. She 
worked with the sitting presidents of black health 
professional advocacy organizations, and a host of civil 
and human rights groups. She tapped as her adviser 
Phyllis Harrison-Ross, Ph.D., professor emeritus of 
psychiatry, who taught her when she was a medical 
student. “In the autumn of my career, she’s again 
instructing me,” says Dr. Perez. A subcommittee of this 
coalition still meets twice a month to provide mental 
health services that to this day are still inadequate. 
Since 2006 Dr. Perez has been the national medical 
director for UPRIS, a Cleveland-based company that 
specializes in health information technology delivered 
in a culturally appropriate manner to promote health 
literacy in patients. The African Methodist Episcopal 
Church (AMEC) uses UPRIS portals, with patient 
consent, to monitor the health of more than 6 million 
congregants. Health information, including culturally 
appropriate prevention messages, can be disseminated 
to congregants via a trusted AMEC portal.
Faith calls
Such ventures spring from Dr. Perez’s intense faith in 
humanity to work toward repairing the world, perhaps 
inspired, as she is, by ardent religious beliefs. Her 
outgoing voice mail message proclaims: God is good, 
and he loves you. “I believe we are spirits having a 
bodily experience,” says Dr. Perez, who in 2002 was 
ordained in the African Methodist Episcopal Church 
while serving as the 102nd president of the National 
Medical Association. In 2006 she adopted the son of 
a family friend struggling with mental illness. “I was 
asked to watch little JayCee for four days,” she says, 
“and in December it will be three years.”
To Dr. Perez, the spiritual beliefs of a patient—how 
often he attends church, his sense of something 
greater than himself—should carry the same weight as 
smoking habits or family history in a medical exam. 
Belief and faith are crucial to healing, she says, and 
“invaluable to the practice of medicine.” 
“You could be wasting resources on drugs, therapy or 
interventions that are not heeded, because they clash 
with someone’s belief system,” she says. “So if I don’t 
explore deeper to tap that belief system, I haven’t led 
you to a path of healing.”p













Through hard work 
and compassion 
for health care 
rights, a nurse 
transforms from 
“on staff” to “in 
charge.”
By L.A. McKeown
It’s late afternoon on a chilly October day and Judith M. Watson, M.P.H. ’07, still hasn’t had lunch. Between  meeting with representatives from a 
local hospital, dealing with staff issues, 
returning emails and telephone calls,  
working on applications for funding,  
preparing a report for the center’s  
governing board and speaking with a  
reporter, her day as executive director of 
the Greenburgh Health Center in White 
Plains, N.Y., has been full, to say the least.
“It’s crazy, but I love it,” Watson says. “I’m 
one of those rare people who love what I 
do. I love waking up and going to work in 
the morning.”
When Watson first walked through the 
doors of Greenburgh in 1994, she was a 
newly-licensed RN who felt she already 
had exceeded her own expectations. She 
had overcome a number of challenges in 
her early years and says she was not a  
typical student. After eight years at  
Greenburgh she was offered the executive 
director position, which she accepted—
along with a whole new set of challenges.
“I’m very fortunate, but my getting this  
position is mostly the result of just plain 
hard work,” she says. Watson credits  
her mentor and boss, Carole Morris, with 
helping her achieve her goals and  
encouraging her to believe in herself.  
Morris, who is the chief executive officer 
of the Mount Vernon Neighborhood Health 
Center Network, of which the Greenburgh 
center is a part, recognized the ambition and 
passion in Watson and offered support and 
guidance as she rose through the ranks, one 
position at a time.
Judith M. Watson, M.P.H. ’07
School of Health Sciences and Practice
Alumni 
Statuesque and upbeat, Judith Watson directs a  
neighborhood health center that revolves around the 
radical idea that health care is a fundamental right of 
every human being, regardless of their ability to pay. 
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“I have worked in each and every department in this health cen-
ter,” Watson says with a laugh. “I have a strong work ethic and I 
became that person who would do whatever was asked of her, 
whatever needed to be done at that moment in time.” Watson 
also credits her three years of active duty in the U.S. Army and 
four more in the Reserves with helping her achieve a “stick with 
it” attitude and hone much-needed organizational skills.
Legacy of Community
As a satellite site of the Mount Vernon Neighborhood Health 
Center Network, the Greenburgh Health Center is one of the 
nation’s 5,000 Federally Qualified Health Centers, or FQHCs. 
The center offers comprehensive, affordable primary health care 
services to its patients, about half of whom are uninsured and 
undocumented. 
“We provide primary health care services regardless of ability 
to pay,” Watson says. “The fee to see a provider is based on a 
sliding scale, but we don’t turn anyone away based on ability or 
inability to pay. Even if they come in with no money on them, 
they would still be able to see a doctor that day.” Due to  
widespread economic woes, Greenburgh has become  
particularly important for many people in the area who have lost 
jobs, and lost insurance, according to Watson. The center also 
accepts patients regardless of immigration status, a policy that 
many health care providers would prefer to avoid.
The Greenburgh center offers everything from pediatrics to 
internal medicine, along with dentistry and ophthalmology all 
under one roof. It also has its own lab to serve the more than 
19,000 registered patients who make 92,000 annual visits to the 
center each year. Watson supervises a staff of 88, including  
providers, nurses, medical assistants and clerical staff. 
Going further, wanting more
Getting the top spot was a major career achievement for Watson, who 
was only 34 years old at the time, but she didn’t stop there. “Once I 
was sitting in this seat I realized I needed to go back to school and get 
my masters degree,” she says. So, at the urging of several colleagues, 
including Vice Dean James O’Brien, Ph.D., who served with her on a 
community board, she enrolled in the Master of Public Health program 
at New York Medical College’s School of Public Health (now called the 
School of Health Sciences and Practice).
Watson’s graduating class was the pilot group for the capstone 
course, a culminating experience that offers a hands-on alternative 
to a thesis. Students are given an in-depth understanding of  
current and emerging areas of critical interest through the analysis 
of actual cases from the annals of public health practice. Watson 
says she was glad to opt for this alternative route to her degree. 
Today, she feels having gone through the Health Policy and 
Management track helped inform and broaden her views on the 
national health care debate.
Expansion and frustration
The need for community health centers is continually growing. 
Under the direction of her CEO Carole Morris, Watson has led 
Greenburgh in attempting an expansion project that would move 
them to a new, larger building and more than triple their  
functional space from 13,000 to 40,000 square feet. But the project 
has been fraught with obstacles, mainly due to members of the 
community who have objected to having a health center in their 
neighborhood, and who managed to stall the project for 5 years. 
By the time the approvals came, the budget had doubled from $10 
million to a nearly unattainable $20 million.
(continued on page 29)
Lifelong Learner
Like most high school students in her hometown of Mars Hill, Maine, Lynn Bray, M.S. ’01, kept an eye on fashion and the Central Aroostook basketball games. But unlike most of her friends, she enjoyed examining the frogs and earthworms in the dissection lab. Later, she jumped at the chance to watch 
an autopsy while majoring in medical technology at the University of Maine.  
“A group of us went to the morgue at the Eastern Maine Medical Center in Bangor,” 
Mrs. Bray recalls, chuckling over a favorite story. “The seminary students all left 
after one minute. The medical-tech students had their heads right down in it. For 
as long as I can remember, I’ve been interested in science and medical issues.” 
After graduating Phi Beta Kappa, Mrs. Bray began her long and peripatetic career 
as a medical technologist, working in labs in Colorado, Maine and Rhode Island, 
where she performed testing in chemistry, hematology and microbiology. By the 
late 1990s, she was ready to take her career to a new level while her family was 
intent on settling down. They moved to Ridgefield, Conn., where her husband, Jim, 
accepted a ministerial position. 
Back to school
“I looked around at several schools, and New York Medical College had all the 
medical sciences of interest to me,” Mrs. Bray says. “I hadn’t been in school in 25 
years, so I took two summer classes to see if I could do it again. When I’d come 
home and tell Jim what I’d learned, he told me my face would light up.” 
It took her four years to complete her master of science degree in pharmacology, 
because in addition to her studies, she was juggling family life (she and Jim have 
two daughters) and a part-time job with a dermatologist in Ridgefield as a medical 
assistant. Mrs. Bray says she couldn’t have done it without the support she got at 
home and on campus. 
“Jim has always been supportive of me, encouraging me to go back 
to school. And the kids got so excited on graduation day,” Mrs. 
Bray recalls. “Dr. Stier was my advisor, and he was very helpful, 
especially when I was nearing graduation and looking for a job.” 
“Lynn is the type of student that program directors love 
to work with,” says Charles Stier Jr., Ph.D., associate 
professor of pharmacology. “She all but breezed through 
the pharmacology program. She was one of only two 
pharmacology master’s students in the past 20 years 
to finish with a GPA over 3.92, and at graduation she 
was given the Graduate Faculty Council’s award for 
academic excellence. It gives me great pleasure to 
know that she has done so well in her career.”  
A medical technologist’s enduring interest in science and medicine 
has fostered a long career of healing and helping. 
By Lynda McDaniel
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Ask and receive
While reading the Danbury News-Times six years ago, Mrs. Bray noticed 
an ad for a clinical trial in Danbury at the Clinical Research Center of 
Connecticut. Armed with her latest credentials and resume, she stopped 
by the clinic. 
“I asked if they were looking for someone with my qualifications, and I’ve 
been there ever since,” she says. “I know my master’s degree helped me 
get the job. It also helped me understand the pharmacology of the drugs, 
their side effects, and the issues that patients deal with.”  
The Clinical Research Center performs Phase III clinical trials that could 
last anywhere from two weeks to three years. The director is Kenneth 
Miller, M.D., who practices rheumatology on site, treating diseases like 
rheumatoid arthritis, osteoporosis and fibromyalgia. Most of the trials are 
rheumatology related.
Mrs. Bray started as a clinical research coordinator, performing study 
visits according to specific protocols. Her job was to obtain informed 
consent, take medical histories and vital signs, and provide medication 
accountability, data collection and transcription, and query resolution. Last 
year, she earned a promotion to site manager/clinical research coordinator 
and now oversees the day-to-day operations of the research center.  
Mrs. Bray considers the patients’ welfare as her most important task. In 
addition to complying with all the FDA regulations—for example, the 
Code of Federal Regulations (CFR) or Good Clinical Practices (GCP)—she 
focuses on the participants and ensures that they understand what may lie 
ahead as they go through a trial.  
As site manager, Mrs. Bray oversees as many as 10 studies at once and all 
the protocols for each study. It’s a detail-rich job that includes reviewing 
all medications at every visit—right down to the aspirin they took last 
Tuesday or the vitamin C they swallowed to fend off a cold.  
“Even if they stubbed a toe or had a car accident—it’s important that 
we know anything that happened to them since we saw them last,” 
Mrs. Bray adds. “Then Dr. Miller determines if that occurrence had any 
relationship to the drug in the study. We pass this information on to the 
pharmaceutical manufacturer so they can develop a list of possible side 
effects. Of course, even with 1,000 people in a trial, not every side effect 
will come out until the drug is on the market. To the best of our ability, 
we record all the side effects from the group we work with.”  
R&R from CFR
Mrs. Bray’s life is not all science. She’s close to her family, which is 
growing up fast. Sarah, their older daughter, is in her fourth year of 
medicine at the University of Pittsburgh. Rebekah is getting her master’s 
degree in teaching foreign language at Wake Forest University in North 
Carolina.  That leaves Mrs. Bray a little more time for reading, especially 
mysteries: “My work can be so intense that part of my home routine is to 
purposefully seek relaxation.” 
At day’s end, the busy pace and the extra work to ensure the most 
accurate results are worth it if it helps people live better lives. 
“I find it extremely gratifying when patients do well in trials and get relief. 
Fibromyalgia patients, for example, are ecstatic. They tell us that we’ve 
given them their lives back. They are pain free and can function in ways 
they haven’t been able to. That’s a wonderful feeling,” she reveals. p
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For those who participate in clinical research studies supervised 
by Lynn Bray, her meticulous attention to detail helps keep them 
informed and protected. The fact that such clinical trials often lead 
to better and more effective treatments is an attractive bonus.
Milestones
’07
Josh Rubin, M.D. ’07, is an 
anesthesiologist at St. Barnabas 
Medical Center in Livingston, N.J.
’06
Joshua Quick, M.D. ’06, 
completed deployment with the 
26th Marine Expeditionary Unit 
and has been assigned as a flight 
surgeon for the Marine Medium 
Tiltrotor Training Squadron 204, 
the “Raptors,” as well as for the 
Marine Tiltrotor Operational Test 
and Evaluation Squadron 22, the 
“Argo Nuts.”
’04
Michael G. Lewis, M.D. ’04, 
a graduate of Fifth Pathway 
(now called the Pre-Internship 
Program), successfully completed 
his pediatric residency training 
at Nassau University Medical 
Center on Long Island. He is  
currently practicing pediatrics  
at Notchview Pediatrics in 
Clifton, N.J.
’02
Daryl Sulit, M.D. ’02, has  
completed his dermatology 
residency at the Naval Medical 
Center in San Diego.
the90s
Matthew Deeter, M.D. ’98, 
a trauma surgeon and U.S. 
Army Major, has been working 
with Doctors Without Borders 
in Baghdad, Mosul and most 
recently, Sri Lanka. Dr. Deeter 
and his wife, Kristina Heer 
Deeter, M.D. ’98, and their 
two daughters will be moving to 
Miami when he returns. He plans 
to start a surgical critical care 
fellowship at Jackson Memorial 
Hospital, while his wife practices 
pediatric intensive care at Joe 
DiMaggio Children’s Hospital.
Sushma Jois, M.S., ’97, is a 
nutritionist for the Kingsland 
Dieticians Group in Katy, Tex.
Felix E. Shepard Jr., M.D. 
’93, is in a solo urology private 
practice in Norton, Va.
Elaine Klinge Schwartz, M.D. 
’90, is an associate professor 
of medicine at National Jewish 
Health in Denver. Dr. Schwartz’s 
clinical responsibilities include 
pulmonary and critical care 
medicine. She is also involved in 
teaching residents and fellows. 
Dr. Schwartz is the mother of 
four “very beautiful and active 
children!”
the80s
Renee Kohanski, M.D. ’87, 
continues to write columns for 
Talkers magazine, while husband 
Philip Kohanski, M.D. ’90, is 
state champion for Connecticut 
pistol matches.
Andre A. Konski, M.D. ’84, a 
radiation oncologist, is professor 
and chairman of the depart-
ment of radiation oncology at 
Wayne State University School of 
Medicine in Detroit, and chief of 
radiation therapy at the  
Karmanos Cancer Center.
Richard Sturm, M.D. ’83, a 
board certified ophthalmologist 
specializing in glaucoma and  
cataract surgery, is a partner at  
Ophthalmic Consultants of Long 
Island. Dr. Sturm has participated 
in the Mission Cataract USA pro-
gram, offering free cataract surgery 
to residents of Long Island.
Jonathan D. Kunis, M.D. ’82, 
is in his fourth year as assistant 
medical director at Health-
care Connection, a residential 
treatment center for chemical 
dependence in Tampa.  
Dr. Kunis, an addiction medicine 
specialist and internist, received 
board certification from the 
American Board of Addiction 
Medicine.
Stephen J. Nicholas, M.D. ’86
Since he’s a physician, saving a life probably could be regarded as part of the job—except that Stephen J. Nicholas, M.D. ’86, was nowhere near his job last August when he resuscitated a youngster who’d been found nearly drowned, 
unconscious and blue. 
“He had been under water for several minutes,” Dr. Nicholas said of 12-year-old 
Scott Irwin, who hit his head on a jetty while boogie-boarding at a Long Island 
beach. “I cleared his airway and resuscitated him for eight to ten minutes before he 
responded. I was concerned we’d lose him.” Not only did Dr. Nicholas save Scott’s 
life—with his own five children looking on—he also resuscitated Scott’s love for the 
ocean by taking the boy for a jet-ski ride a week later.
Opportunities for heroism are rare, and yet Dr. Nicholas seems to have a sixth 
sense for them. While jogging in Central Park one day in 1986, shortly after  
receiving his M.D. from New York Medical College, he revived a fellow runner who 
was having a heart attack. “It was my first day of being a doctor,” he recalls. Since 
then, he has demonstrated his heroism dozens of times and in November received 
honors at a “Summer of Heroes” event at the Intrepid Sea, Air and Space Museum, 
where museum president Bill White and Nassau County Executive Thomas R. Suozzi 
commended him for his charitable work in New York City. 
It is all part of the job Dr. Nicholas knew he wanted from the time he watched his 
father, the late James Nicholas, M.D., operate on the very famous knee of football 
star Joe Namath. The elder Dr. Nicholas, a prominent orthopedic surgeon credited 
with creating the field of sports medicine, cared for numerous top sports teams, 
including the New York Knicks and the New York Rangers. “That’s how I became 
interested,” the son says.
It was also his personal love of sports, his fascination with science and the body’s 
mechanics, and the satisfaction of restoring an injured patient’s ability to enjoy an ac-
tive lifestyle that drew him to the specialty more than 20 years ago. “There is some-
thing great about taking care of somebody who comes to you with an injury and 
By Andrea Kott, M.P.H.
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Brian Solow, M.D. ’82, 
is medical director for 
Prescription Solutions, a 
national pharmacy benefit 
manager headquartered in 
Irvine, Calif.
Alan J. Conrad, M.D. ’81, 
an internist with the North 
County Internists Medical 
Corporation in Poway, Calif., 
received his master’s degree 
in medical management 
from the Marshall School of 
Business at the University of 
Southern California.
Charles Paidas, M.D. ’81, 
is dean for graduate medical 
education and executive 
associate dean for clini-
cal and extramural affairs 
at the University of South 
Florida College of Medicine 
in Tampa. 
William C. Reha, M.D. ’81, 
M.B.A., was honored with 
the 2009 Clarence A. Holland 
Award, presented annually to a 
Virginia physician for outstand-
ing contributions promoting the 
art and science of medicine and 
the betterment of public health 
through political service.
Lisa Borg, M.D. ’80, board cer-
tified in psychiatry and addiction 
psychiatry, is a senior research 
associate and associate attending 
physician at the Rockefeller Uni-
versity in the Laboratory of the 
Biology of Addictive Diseases. Dr. 
Borg’s areas of interest include 
the clinical neurobiology and ge-
netics of addictive diseases. She 
is also clinical assistant professor 
on the voluntary faculty at Weill 
Cornell Medical School. Dr. Borg 
maintains a private practice on 
the Upper East Side of Manhat-
tan. She has three children.
By Andrea Kott, M.P.H.
wants to return to the way they were.” says the surgeon, who observed 
his first knee operation at age five.
Dr. Nicholas talks fast. That could be because he divides his time among 
four practice locations and has a lot of ground to cover. He is a renowned 
sports medicine specialist—one of New York Magazine’s “Top Doctors” for 
the past 10 years who has served as team doctor for the New York Jets, 
New Jersey Gladiators, New York Islanders, and professional roller hockey 
teams. He is also a recreational athlete who played football, baseball, 
hockey and basketball in college.
A native New Yorker, Dr. Nicholas earned his undergraduate degree from 
Harvard University. After medical school, he completed a residency in 
orthopedic surgery at the Hospital for Special Surgery and a fellowship in 
sports medicine at Lenox Hill Hospital, both in Manhattan. He has  
received numerous honors, including a spot in the National Football Foun-
dation and College Hall of Fame. Founder and director of NY  
Orthopedics, Dr. Nicholas also directs the Nicholas Institute of Sports 
Medicine and Athletic Trauma at Lenox Hill. 
There is no denying the thrill of caring for the high-profile bones and joints 
of a New York Jet. “Seeing an NFL running back run 1,500 yards or throw a 
ball 60 yards … you know you’ve done everything you possibly can when 
you see an athlete return to a high level of function,” he says. At the same 
time, there is no missing Dr. Nicholas’ fierce commitment to helping average 
recreational athletes maintain their active lifestyles. “What about the 60-year-
old who likes to play tennis three days a week?” he points out.
“Athletics is something we want everybody to do,” he continues. “If they’re 
not able to do it because of some injury or defect in their body, it’s up to 
us to help them maintain their quality of life.”
Passionate as he is about sports medicine, however, Dr. Nicholas voices 
concern about the patients needing it most these days: school-age athletes. 
The growth of year-round, school-based team sports, along with a move 
toward encouraging youngsters to specialize and compete in a single 
sport, have increased the incidence of repetitive, potentially debilitating 
injuries at earlier ages. 
Kids who play baseball year-round, for example, are throwing the ball 
more and suffering more overuse of arm muscles and ligaments because 
their bodies don’t have time to heal, Dr. Nicholas laments. “Parents are 
coming in and asking to have their children operated on at an early age 
because they want their kids to become professional athletes,” he says. 
“They want the Tommy John procedure so their kids can throw farther,” 
describing an operation named for a Los Angeles Dodgers pitcher. The 
surgery reconstructs the ulnar collateral ligament (UCL) by using a tendon 
from the forearm to improve the stability of the elbow joint.
“We’re operating on these kids at a much younger age than we used to,” 
Dr. Nicholas says. “Fitness at an earlier stage is great, but specialization is 
beginning to take its toll.” So, as he cares for younger and younger athletes, 
he also urges them to train in a variety of sports and athletic activities so 
they can stay active, and uninjured, longer.
The ultimate goal for this doctor-athlete is to keep his patients, whether 
amateurs or pros, on the field: “ When they come back into the office for 
a checkup five months after I’ve fixed them—that’s a tremendous sense of 
satisfaction.”p
Judith M. Watson, M.P.H. ’07
(continued from page 25)
(continued on next page)
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“This is my biggest disappointment professionally,” Watson says. 
“We spent years convincing people why we had to move forward 
and now the budget is all but out of reach.”
However, under the American Recovery and Reinvestment Act 
(ARRA) of 2009, otherwise known as the government stimulus 
package, funds are being made available to a limited number of 
community health centers for expansion of services and infrastruc-
ture.  Greenburgh has applied for a share of those funds to help 
them build their new center. “It’s a long shot, but if we get it, it 
will be a major victory,” Watson says. [At press time, she still had 
not heard the results of her application.]
Despite the many demands and pressures of her job, Watson 
says she couldn’t see herself doing anything else. When she’s not 
working, she’s usually jogging or spending time with friends and 
her large, close-knit family, including 6-year old niece Dream, 
whom Watson calls “the light of my life.”
While it’s easy to become frustrated over the complex and prob-
lematic state of health care today, Watson says working at the 
Greenburgh Health Center satisfies her core belief that everyone 
is entitled to the same basic medical services. “Health care is the 
right of every human being,” she asserts. “The fact that I’m part of 




ovitz, M.D. ’79, is director of 
the CT unit at Kaplan Hospital 
in Rehovot, Israel, where she 
has been living since 1986. Dr. 
Herskovitz’s oldest son, Yaakov, 
is studying for his master’s in 
Hebrew literature at Hebrew 
University in Jerusalem. Her 
second son, Netanel, who was 
injured in a suicide bomber  
attack in 2001, has been study-
ing occupational therapy at Haifa 
University. Her daughter Re’ut 
(which means “comradeship”) is 
in sixth grade.
Jennifer Thulin, M.D. ’79, 
has been working in a private 
gynecology practice in the  
Boston suburbs for more than 
25 years and would welcome 
any contact from classmates.  
Philip A. Kern, M.D. ’78, is 
director of the Barnstable-
Brown Diabetes and Obesity 
Center at the University of 
Kentucky College of  
Medicine in Lexington.
Robert Broderick, M.D. 
’77, is an attending ophthal-
mologist at St. Francis Hospi-
tal and Island Eye Surgicenter 
and a partner at Ophthalmic 
Consultants of Long Island. 
Dr. Broderick participates in 
the Mission Cataract USA 
program, which offers free 
cataract surgery to residents 
of Long Island who cannot 
afford the surgery. Dr.  
Broderick is also on the 
Board of the American  
College of Surgeons  
Credentialing Committee, 
is a Fellow of the American 
Academy of Ophthalmology, 
the American College of  
Surgeons, and is a member of 
the American Society of Cata-
ract and Refractive Surgery.
Scott Cutler, M.D. ’77, is in 
his 28th year as a private prac-
tice, adult clinical psychiatrist 
in Worcester, Mass., and re-
cently opened a second office 
in New York City. Dr. Cutler 
writes that daughter, Beth 
Cutler, M.D. ’06, is starting 
her fourth year of a general 
surgical residency at St. Luke’s-
Roosevelt Hospital Center.
Maxine S. Jochelson, M.D. 
’77, a board-certified diagnos-
tic radiologist, is director of 
radiology for the new breast 
and imaging center at Memo-
rial Sloan-Kettering Cancer 
Center in New York City. Dr. 
Jochelson completed her resi-
dency at Los Angeles County 
Hospital-USC Medical Center 
and a fellowship at the Dana 
Farber Cancer Institute. 
Prior to joining the MSKCC 
faculty, she was an attending 
radiologist at Tarzana Medical 
Center in California, and co-
director of the San Fernando 
Valley Women’s Center.
Barry S. Leitman, M.D. 
’75, is a professor of 
radiology at NYU School of 
Medicine and NYU Medical 
Center. Recently inducted 
as a Fellow of the American 
College of Radiology, Dr. 
Leitman also belongs to the 
Radiological Society of North 
America, American Roentgen 
Ray Society, and the Society 
of Thoracic Radiology.
Jack Albert, M.D. ’74, 
writes that daughter Amanda 
earned her master’s degree 
in piano performance at 
W hen we last met Joan Liman (Chironian Spring/Summer 2005), her plate was already full. She was working as as-
sistant dean and deputy to the medical director at 
Metropolitan Hospital Center, she was volunteering 
for Amas, a non-profit, multi-ethnic theatrical organi-
zation, and she was not quite five years along in her 
recovery from a mastectomy and chemotherapy for 
Stage 3 breast cancer. It was her second bout with 
cancer in 20 years—she was treated for Stage 4 
non-Hodgkin’s lymphoma in 1981.
An indefatigable survivor, Dr. Liman has a plate that 
is fuller than ever. Now retired from Metropolitan 
and the College, she has become president of Amas, 
as well as an occasional co-producer. She is the 
engine behind LimanAde Productions, a fundraising 
venture that features readings of original works at 
her New York City apartment. Rounding out her 
involvement in the arts, she works as a docent for 
the Museum of Jewish Heritage in Battery Park.  
Oh, and one more, very important thing. She is a 
new grandmother.
Joan P. Liman, M.D. ’83, 
M.P.H. ’93
having more time for 
Retirement Means
By Andrea Kott, M.P.H.
“Ryan Levi Gottlieb was born June 10, 2008,” Dr. 
Liman says, heading off the question. Grand-
motherhood moved Dr. Liman to retire more 
than a year ago, and when she is not visiting Ryan, 
she is co-producing one of Amas’ upcoming 
productions. Signs of Life: A Tale of Terezin is a play 
about life in Theresienstadt, a Jewish ghetto set 
up by the Nazis in the former Czechoslovakia. 
“Theresienstadt, or Terezin in Czech, was where 
they gathered many Jews with an artistic bent,” 
Dr. Liman said, explaining how the Nazis forced 
prisoners to produce shows to convince the 
public that it was merely an artist’s colony.
The play originated nine years ago after its 
commercial producer, Virginia Criste, learned 
that her grandparents were on the last transport 
from Theresienstadt to Auschwitz, where they 
perished. When Criste initially visited  
Theresienstadt in the early 1990s, she found a 
makeshift museum with inhabitants’ art hanging 
on the walls and rows of bulletin boards with 
exhibits of tickets and programs from  
performances. Criste envisioned a theater lobby 
filled with Theresienstadt remnants and that 
became the genesis for the show. 
“This is a beautiful piece of theater and a story 
that must be told,” Dr. Liman said. “There is a 
generation of school children and, sadly, adults 
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Northwestern University and 
is in her first year of a doctoral 
program at the University of 
Houston. Son Josh, an 11th-
grader, is a top percussionist at 
Spruce Creek High School in 
Port Orange, Fla.
David J. Beccia, M.D. ’70, is 
celebrating 32 years of practice 
in urology in Bay Shore, N.Y., 
“and still going strong!” Dr. 
Beccia is also celebrating 41 
years of marriage to Jessica, 
and the arrival of their first 
grandchild, Anna, “who is the 
love of our life.” 
the60s
Alan Wecksell, M.D. ’65, 
retired in September 2009.
Nicola Bitetto, M.D. ’64, 
retired in June 2009.
Stephen M. Brenner, M.D. 
’62, is still practicing medicine 
in the Bronx. He is father to 
three adult children, grand-
father to nine, and “enjoying 
it all.”
Michael Schlossberg, M.D. 
’62, retired in 2001 after  
practicing ob-gyn for many 
years. Dr. Schlossberg and wife 
Lana spend their time enjoying 
their children and grandchil-
dren, traveling and collecting 
and studying art. 
Robert Kirschner, M.D. ’61, 
is retired and living in New 
York City.
the50s
Justin Howland, M.D. ’59, 
has published a book, A Califor-
nia Bonesetter’s Autobiography, 
in which he mentions certain 
classmates, along with two 
instructors, Dr. Minervini and 
Dr. Stanley Opler, the latter of 
whom was his employer while 
working at Lenox Hill Hospital. 
Howard Kline, M.D. ’58, 
is still in active practice as a 
cardiology consultant in San 
Francisco and heavily in-
volved in teaching cardiology 
to house staff and cardiology 
fellows. Dr. Kline reports that 
son Christopher is starting 
his fourth year of medical 
school at the College. p
who do not know the history of the Holocaust.” A limited engagement of the 
play is scheduled for February at the Marjorie Deane Little Theatre, located at the 
West Side Y on West 63rd Street in Manhattan.
In addition to becoming a co-producer, Dr. Liman is now a first-time composer, 
having written a quasi-autobiographical musical, A LimanAde Life. A self-described 
“frustrated lyricist” who says she is neither an author nor a composer (“I can 
play by ear and plunk it on the piano!”), she began in 2001 by setting original 
lyrics about her battles with cancer and depression to Broadway show tunes. 
She paired “Lymphoma” with the music of the title song from Oklahoma and  
“Depression” to the melody of “Tradition” from Fiddler on the Roof. 
While ditties about cancer and mental illness may seem like unlikely  
entertainment, Dr. Liman knew she’d have an audience. “One of the reasons I 
think I’m alive today is because of my sense of humor,” she said. “In addition to 
having excellent medical care…maintaining a sense of humor was equally  
important to my medical regimen.” 
The two-act play has received glowing reviews from small audiences at  
Metropolitan Hospital and Hope Lodge, an American Cancer Society-funded 
temporary housing facility for cancer patients and their caregivers.
As for her health, Dr. Liman, 60, just received a clean bill, and she’s not letting any 
grass grow under her feet. In addition to her artistic and family pursuits, she is 
a legislative ambassador for the American Cancer Society. She also works with 
MetPALS, a program she started at Metropolitan Hospital, which teaches minority 
or underserved New York City youth about careers in medicine and health care 
by taking them on field trips and introducing them to healthcare professionals.
It is a busy life, but Joan Liman learned long ago that lots of laughter and  
meaningful work are essential ingredients for health and happiness—after her 
grandson, of course. p
Mitchell L. Goldbaum, M.D. ’87, 
died August 8, 2008.
Dwight M. Pagano, M.D. ’78, died 
July 1, 2009. He was 57.
Steven B. Tamarin, M.D. ’77 (Fifth 
Pathway), died November 30, 2008. 
He was 61.
Jeffrey Behrens, M.D. ’76, died June 
9, 2009. He was 57.
Allan Jacobs, M.D. ’69, died August 
29, 2008.
Patrick J. Dwyer, M.D. ’66, died 
August 12, 2009. He was 70.
Jaime Olivo, M.D. ’64, died  
October 15, 2009. He was 70.
Arthur J. Grahl, M.D. ’61, died 
December 17, 2008.
Allen F. Langhorne, M.D. ’61, died 
July 28, 2009. He was 82.
Kenneth M. Young, M.D. ’61, died 
October 21, 2008. He was 74.
Richard A. Giery, M.D. ’60, died 
August 5, 2008.
Buck J. Williams, M.D. ’60, died 
July 2, 2009. He was 74.
John M. Marino, M.D. ’59, died July 
9, 2009. He was 75.
Roland K. Molinet, M.D. ’59, died 
August 8, 2009. He was 76.
James A. Holleran, M.D. ’56, died 
May 31, 2009. He was 78,
William H. Nass, M.D. ’56, died 
September 16, 2009.
Lawrence A. Norton, M.D. ’56, 
died May 13, 2009. He was 78.
Ernest J. Petrulio, M.D. ’55, died 
October 20, 2008. He was 80.
Melvin A. Scharfman, M.D. ’54, 
died October 18, 2008. He was 80.
John H. Small, M.D. ’54, died July 
29, 2009.
Richard McManus, M.D. ’53, died 
August 18, 2009. He was 81.
Norman M. Brust, M.D. ’51, died 
July 26, 2009. He was 86.
Norman Chu, M.D. ’51, died 
October 22, 2008. 
Benjamin Nicotri, M.D. ’50, died 
July 30, 2009. He was 90.
Edward A. Clerkin, M.D. ’48, 
died June 25, 2009. He was 85. 
Miguel A. Figueroa, M.D. ’48, 
died May 25, 2009. He was 86.
Robert M. Ahrens, Sr., M.D. ’47, 
died February 24, 2008.
James B. Lynch, M.D. ’47, died 
June 25, 2009. He was 86.
Robert S. Bailey, M.D. ’43, died 
October 21, 2009. He was 93.
Marvin A. Humphrey, M.D. ’43, 
died July 22, 2009.
Joseph B. Enders, M.D. ’41, died 
September 18, 2009.
Joseph Sarullo, M.D. ’41, died 
May 28, 2009. He was 95.
Roger D. Sherman, M.D. ’40, 
died May 15, 2009. He was 93.
Charles P. Vialotti, M.D. ’36, died 
February 24, 2009.
Faculty
Sidney Berezin, M.D., clinical 
assistant professor of pediatrics, died 
in October 2009. He was the father 
of Stuart H. Berezin, M.D., associate 
professor of pediatrics and chief 
of pediatric gastroenterology at 
Westchester Medical Center.
John F. Gillooley, M.D., clinical  
associate professor of pathology 
who retired as chairman of  
Pathology at St. Vincent’s Hospital, 
Manhattan, died in June, 2009. 
Among many achievements, he 
pioneered histologic grades in the 
prognosis of breast cancer, and was 
one of the first practitioners at the 
beginning of the AIDS epidemic to 
recognize the significance of Kaposi’s 
sarcoma in diagnosing the disease.
Board of Trustees
Patricia Mosbacher, honorary 
trustee, died in February 2009.
In Memoriam
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of weight gain, waist gain and white-coat hypertension 
in women and its role as an alphabetic and chronologic 
antecedent to the better known Syndrome X.  
In conjunction with colleagues at Montefiore Medical  
Center and the University of Tennessee (Memphis),  
Dr. Mogul is conducting a multicenter study that targets 
women with Syndrome W.  This double blind, placebo  
controlled, randomized clinical trial evaluates efficacy and 
safety of metformin—a diabetes drug known to  
decrease insulin resistance and promote weight loss 
—and metformin plus low dose rosiglitazone (another 
diabetes medication) as an adjunct to a carbohydrate 
modified diet and behavioral strategies. Participants  
attended weekly nutrition workshops where they were 
introduced to the EMPOWIR dietary intervention. 
Data from 49 subjects were presented at the annual  
meeting of The Obesity Society in October, 2009. Changes 
in body weight were significant and comparable at two 
study sites. Earlier research supports hypotheses that  
insulin elevation could be a cause, as well as a  
consequence, of weight gain, accounting for progressive 
and intractable menopausal weight gain.
“EMPOWIR: Enhance the Metabolic Profile  
of Women with Insulin Resistance.” Poster 
presented at the annual meeting of The Obesity Society, 
October, 2009. p
Leading Edge 
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At the Sesquicentennial Dinner, held October 17, 2009, at Glen Harbour Island 
in New Rochelle, N.Y., the College’s 150th anniversary celebration was formally 
launched. The honoree was the College itself—its students, faculty, alumni and 
staff—and guests enjoyed a short video depicting the College’s illustrious history.
Sesquicentennial Dinner Celebration
  1.  William Dieck, M.D., Eileen M. Dieck, M.D. ’86, met  
up with Patricia Barry, M.D. ’83, and John Cosgrove, 
M.D. ’83.
  2.  A special award was given to Saverio S. Bentivegna, 
M.D. ’50. He was joined by his wife Kathleen, and 
Ingrid Connolly. 
3.  Enjoying the gala were Assemblywoman Amy Paulin 
and Ronald F. Poe, chairman of the Board of Trustees.
  4.  Among the more than 400 guests at the black tie  
celebration dinner were David Asprinio, M.D.,  
chairman of orthopedic surgery, and Matthew  
Harris, M.D. 
  5.  Robert W. Amler, M.D., dean of the School of Health 
Sciences and Practice, shared a laugh with New York 
State Senator Suzi Oppenheimer, Karl P. Adler, M.D., 
president and CEO, and Mr. Poe.
  6.  Drs. Adler and Amler accepted a proclamation 
presented by New York State Senator Andrea 
Stewart-Cousins.
  7.  Dr. Adler presented a plaque to Dr. Lee Dieck,  
Alumni Association President.  
 8.  Graduate School of Basic Medical Sciences Dean 
Francis L. Belloni, Ph.D., enjoyed a dance with his  
wife, Margaret Ciarcia.  
  9.  John Fallon III, M.D., Ph.D., chairman of pathology,  
and his wife Mary chatted with William H. Frishman, 
M.D., professor and chairman of medicine, and  
his wife Esther.
10.  Ralph A. O’Connell, M.D., provost and dean of the 
School of Medicine, and Dr. Adler surveyed the  
lively scene.
11.  Joseph F. Dursi, M.D. ’59, served as Master  
of Ceremonies.
12.  Michael A. Antonelle, M.D. ’62, greeted Samuel H. 
Rubin, M.D., provost and dean emeritus.
13.  Dr. Adler accepted an official proclamation from 
Westchester County Executive Andrew J. Spano.
14.  Among the guests were College trustee Maureen 
Roxe and her husband Joe Roxe of Darien.
15.  Sen. Oppenheimer and her husband Martin J.  
Oppenheimer chatted with Dean Amler and Sherlita 
Amler, M.D., Putnam County Health Commissioner, 
who is also a faculty member.
16.  Dr. John Connolly, former president of New York 
Medical College, and his wife Ingrid, far left, chatted 
with Jane O’Connell.
17.  Joseph Giamelli, M.D.’02, and his wife Anna enjoyed 
the dancing with their daughter Samantha.
18.  Joining the festivities were Edmund F. LaGamma, M.D. 
’76, and his wife Kalliope.
19.  Representing the university’s three schools were 
students Obiageli Nwankwo (Health Sciences and 
Practice), Candace Ford (Basic Sciences) and Stephen 
Rotman (Medicine).
10. 9. 
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